We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+11.43%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$990M
AUM Growth
-$95.1M
Cap. Flow
-$12.4M
Cap. Flow %
-1.25%
Top 10 Hldgs %
70.6%
Holding
53
New
12
Increased
7
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$58.8M
2
MORF
Morphic Holding, Inc. Common Stock
MORF
+$42.9M
3
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$34.9M
4
BCEL
Atreca, Inc. Class A Common Stock
BCEL
+$26.8M
5
CYCN icon
Cyclerion Therapeutics
CYCN
+$11M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$42.5M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$31.3M
3
ARGX icon
argenx
ARGX
+$31M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$24.9M
5
DNTH icon
Dianthus Therapeutics
DNTH
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
2 Miscellaneous 1.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KURA icon
1
Kura Oncology
KURA
$1.13B
$104M 10.5%
5,276,753
– –
XNCR icon
2
Xencor
XNCR
$1.94B
$95.6M 9.66%
2,336,557
+277,128
+13% +$9.1M
ARGX icon
3
argenx
ARGX
$64B
$82.3M 8.31%
581,165
-243,922
-30% -$31M
CRSP icon
4
CRISPR Therapeutics
CRSP
$5.58B
$75.8M 7.66%
1,610,250
-268,027
-14% -$10.7M
KYNB
5
Kyntra Bio
KYNB
$32.5M
$68.3M 6.9%
60,471
+53,736
+798% +$58.8M
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$62.9M 6.35%
614,128
+85,128
+16% +$9.19M
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$61.6M 6.22%
597,711
-402,289
-40% -$31.3M
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$52.2M 5.28%
3,316,407
– –
IRWD icon
9
Ironwood Pharmaceuticals
IRWD
$682M
$51.1M 5.16%
4,671,408
-578,811
-11% -$6.48M
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$44.9M 4.54%
+2,266,804
New +$42.9M
RARE icon
11
Ultragenyx Pharmaceutical
RARE
$2.52B
$31.6M 3.19%
497,899
– –
PRVL
12
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$31.6M 3.19%
+2,392,556
New +$34.9M
BCEL
13
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$28M 2.83%
+1,486,979
New +$26.8M
CHMA
14
DELISTED
Chiasma, Inc. Common Stock
CHMA
$22.7M 2.3%
3,043,827
– –
HARP
15
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$17.5M 1.77%
134,842
+1,200
+0.9% +$139K
GOSS icon
16
Gossamer Bio
GOSS
$83.2M
$17.1M 1.73%
772,096
– –
ARQL
17
DELISTED
Arqule Inc
ARQL
$14.3M 1.45%
+1,300,000
New +$9.05M
KYNB
18
CALL
Kyntra Bio
KYNB
$32.5M
$12.5M 1.27%
11,100
-6,532
-37% -$7.15M
EIGR
19
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$12M 1.22%
37,868
-15,320
-29% -$5.3M
RCUS icon
20
Arcus Biosciences
RCUS
$3.72B
$11.8M 1.19%
1,488,205
+498,059
+50% +$4.99M
UBX
21
DELISTED
Unity Biotechnology
UBX
$9.92M 1%
104,450
+13,789
+15% +$1.17M
CYCN icon
22
Cyclerion Therapeutics
CYCN
$17.7M
$8.89M 0.9%
+38,810
New +$11M
PRTA icon
23
Prothena Corp
PRTA
$479M
$7.64M 0.77%
723,300
-3,219
-0.4% -$33.1K
RUBY
24
DELISTED
Rubius Therapeutics, Inc
RUBY
$7.29M 0.74%
463,152
-183,076
-28% -$2.95M
ASMB icon
25
CALL
Assembly Biosciences
ASMB
$694M
$6.72M 0.68%
+41,525
New +$7.89M
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2019 Portfolio in Review

As of Q2 2019, EcoR1 Capital held 53 positions worth $990M, down 8.8% from $1.08B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

EcoR1 Capital's Q2 2019 filing shows 12 new, 7 increased, 12 reduced and 14 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 2,266,804 shares worth $44.9M. The largest sale was Ascendis Pharma A/S, an estimated $42.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q2 2019 buy was Morphic Holding, Inc. Common Stock: 2,266,804 shares worth $44.9M.
  • EcoR1 Capital added most to Kyntra Bio in Q2 2019, an estimated $58.8M increase.
  • EcoR1 Capital's biggest Q2 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $31.3M.
  • EcoR1 Capital fully exited Ascendis Pharma A/S in Q2 2019, selling an estimated $42.5M.
  • EcoR1 Capital's ten largest holdings make up 71% of its $990M portfolio in Q2 2019.
  • EcoR1 Capital opened 12 new positions and closed 14 in Q2 2019.
  • EcoR1 Capital's portfolio value fell 8.8% quarter-over-quarter to $990M.

Based on EcoR1 Capital's 13F filing for Q2 2019, filed 14 Aug 2019.